These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35857825)

  • 21. Evaluation of the humoral and mucosal immune response of a multiepitope vaccine against COVID-19 in pigs.
    Mosqueda J; Hernández-Silva DJ; Vega-López MA; Vega-Rojas LJ; Beltrán R; Velasco-Elizondo A; Ramírez-Estudillo MDC; Fragoso-Saavedra M; Pérez-Almeida C; Hernández J; Melgoza-González EA; Hinojosa-Trujillo D; Mercado-Uriostegui MÁ; Mejía-López AS; Rivera-Ballesteros C; García-Gasca T
    Front Immunol; 2023; 14():1276950. PubMed ID: 38179057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.
    Xiao L; Yu W; Shen L; Yan W; Qi J; Hu T
    ACS Appl Mater Interfaces; 2023 Aug; 15(30):35895-35905. PubMed ID: 37466148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
    Du Y; Xu Y; Feng J; Hu L; Zhang Y; Zhang B; Guo W; Mai R; Chen L; Fang J; Zhang H; Peng T
    Vaccine; 2021 Apr; 39(16):2280-2287. PubMed ID: 33731271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1.
    Li X; Xu M; Yang J; Zhou L; Liu L; Li M; Wang S; Liu MQ; Huang Z; Zhang Z; Liu S; Hu Y; Lin H; Liu B; Sun Y; Wu Q; Shi ZL; Lan K; Chen Y; Yan H; Chen YQ
    Signal Transduct Target Ther; 2024 Apr; 9(1):114. PubMed ID: 38678055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.
    Ma C; Li Y; Wang L; Zhao G; Tao X; Tseng CT; Zhou Y; Du L; Jiang S
    Vaccine; 2014 Apr; 32(18):2100-8. PubMed ID: 24560617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
    Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
    Front Immunol; 2021; 12():744887. PubMed ID: 34712232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.
    Cristillo AD; Ferrari MG; Hudacik L; Lewis B; Galmin L; Bowen B; Thompson D; Petrovsky N; Markham P; Pal R
    J Gen Virol; 2011 Jan; 92(Pt 1):128-40. PubMed ID: 21169215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2.
    Fragoso-Saavedra M; Ramírez-Estudillo C; Peláez-González DL; Ramos-Flores JO; Torres-Franco G; Núñez-Muñoz L; Marcelino-Pérez G; Segura-Covarrubias MG; González-González R; Ruiz-Medrano R; Xoconostle-Cázares B; Gayosso-Vázquez A; Reyes-Maya S; Ramírez-Andoney V; Alonso-Morales RA; Vega-López MA
    Front Immunol; 2022; 13():848054. PubMed ID: 35432364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
    Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
    Front Immunol; 2022; 13():858904. PubMed ID: 35592324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and immunological activity evaluation of an intranasal protein subunit vaccine against ancestral and mutant SARS-CoV-2 with curdlan sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant.
    Chen Y; Wang Y; Li Z; Jiang H; Pan W; Liu M; Jiang W; Zhang X; Wang F
    Int J Biol Macromol; 2024 Sep; 276(Pt 1):133733. PubMed ID: 39002905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses.
    Puhach O; Bellon M; Adea K; Bekliz M; Hosszu-Fellous K; Sattonnet P; Hulo N; Kaiser L; Eckerle I; Meyer B
    EBioMedicine; 2023 Dec; 98():104893. PubMed ID: 38035462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
    Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
    Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody.
    Cao X; Zai J; Zhao Q; Xie L; Li Y
    Vaccine; 2022 Sep; 40(40):5757-5763. PubMed ID: 36055873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice.
    Li J; Hsu KS; Howe SE; Hoang T; Xia Z; Berzofsky JA; Sui Y
    Front Immunol; 2024; 15():1386243. PubMed ID: 38835757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.
    Yang H; Xie Y; Li S; Bao C; Wang J; Li C; Nie J; Quan Y
    Hum Vaccin Immunother; 2024 Dec; 20(1):2364519. PubMed ID: 38880868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination.
    Ishizaka A; Koga M; Mizutani T; Uraki R; Yamayoshi S; Iwatsuki-Horimoto K; Yamamoto S; Imai M; Tsutsumi T; Suzuki Y; Kawaoka Y; Yotsuyanagi H
    Virol J; 2023 Jul; 20(1):146. PubMed ID: 37443091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal and sublingual delivery of inactivated polio vaccine.
    Kraan H; Soema P; Amorij JP; Kersten G
    Vaccine; 2017 May; 35(20):2647-2653. PubMed ID: 28400164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
    Jones DI; Pollara JJ; Johnson-Weaver BT; LaBranche CC; Montefiori DC; Pickup DJ; Permar SR; Abraham SN; Maddaloni M; Pascual DW; Staats HF
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.